Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Insights: Why invest in Asia? An introduction to EM and Asian markets

Asia represents nearly a fifth of global GDP – yet it remains one of the most underrepresented regions in investor portfolios. From compelling valuations and structural growth opportunities to low correlation with Australian and global indices, the case for a dedicated allocation to Asian equities is stronger than many investors realise.

Portfolio Manager, John Stavliotis explains why the emerging markets cycle may be turning, why Asia offers a genuinely differentiated opportunity set, and how Antipodes’ pragmatic value approach is designed to capture it.

 

Transcript

Welcome to another Antipodes Insights video. Today we’ll be focused on EM and Asian equities. I’m joined by John Stavliotis, portfolio manager for the Antipodes Emerging Markets, Asia and China funds. Welcome, John. Thanks for having me.
Jonathan: With regards to Asia, when we’re talking to investors, it’s always continually being the great unknown known. Investors are aware of what it’s made up of and what its potential is, but what they’re unaware of is its natural underweight in a lot of the global indices, especially if you are targeting a particular asset allocation.

So John, why should investors consider having a bespoke allocation to Asia?

Asia is important in the world, and that really gets underemphasised. If you look at China as a proxy for Asia – China’s population as a percentage of world is about 17%, of GDP it’s about 18%, and if you use total market cap weighted global market cap, China’s high teens–percentage. But in the MSCI All Country World Index it’s 3.8%. And most people are probably invested in the MSCI World, which doesn’t have any emerging markets in it.

In many portfolios, Asia is underrepresented. The reason is you’ve got higher growth in Asia at a GDP level. You can get exposure to the underlying developments of these economies which is that GDP growth, but you can also get exposure to structural opportunities like tech, hardware and supply chain, which is all in Asia. And Asia is cheaper than what you’re currently paying for companies in the US. China is currently trading at about 13 times PE. Indonesia is trading at the 25th percentile of where it’s historically traded – a significant discount when most markets are trading way beyond historical levels of valuations.

What about from a correlation perspective if people were to choose that bespoke allocation?

When you’re forming portfolios, you want to have uncorrelated sources of alpha. Asia’s correlation to world indices is about 0.4, and to the Australian index – the MSCI Australia – it’s actually 0.33. So it’s fairly uncorrelated to what you may already have in your portfolio.

Over the last year we’ve seen broad emerging markets and Asia perform very well, and a lot of investors always ask: is this the time to get in? Have I missed out? What’s your view?

Emerging market cycles are quite long, and we’ve been through a quite painful cycle over the last 15 years of underperformance relative to developed markets. We think there are some reasons why that’s changing. Valuation is one I’ve already talked about. The other is the high correlation with US dollar strength and weakness – a weaker US dollar typically helps allocations to EM, and we’re starting to see the US dollar roll over. Interest rates and global growth – We are starting to see global growth improve, and really that US exceptionalism, which is what’s driven that flow of capital to the US, is starting to at least equalise with higher global GDP growth, and we’re seeing that in commodity prices improving. If that continues, we think that EM cycle will be a long cycle on the upside.

Another way to put it in context – the amount of money in the Magnificent Seven is currently over two times the value of the MSCI EM Index. So a little bit of money coming out of the US large caps will have a huge effect on Asian equities or emerging market equities, and that’s why that cycle can last for quite a long time.

Now, if we bring that back to Antipodes — our investment DNA is pragmatic value. What does that mean to you as a portfolio manager for these funds, and why do you think it works in Asia?

Pragmatic value means we’re looking for companies that are cheap relative to the resilience and growth of the business. We use industry-led research to identify these opportunities. Breaking those two things down – industry-led means we’ve got a global team of investment professionals looking at industries on a global perspective. We’ve got an analyst that covers tech globally and they can help us pick stocks in Asia in that tech supply chain. That’s a huge advantage over someone that’s just looking at Asia.

From a pragmatic value approach, you’re investing in Asia for the growth. Our philosophy is value-based – we want companies that are cheap for the growth and resilience. We’re able to identify companies that can benefit from Asia’s growth but that are not currently being priced in the market, and that’s what we think will help us outperform over the long term.

So there you have it – an introduction to Asia and why the investment potential is there. If you have any questions or inquiries, please speak to one of your Antipodes representatives or Pinnacle Investment Management.

Subscribe to receive the latest news and insights from the Antipodes team

IMPORTANT INFORMATION:
This information has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Antipodes China Fund (ARSN 116 380 771) (‘Fund’) and the Antipodes Asia Fund (ARSN 134 226 029) (‘Fund’). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Antipodes China and Asia Funds. MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526). This report contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.
Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks referred to may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at www.antipodes.com or by calling 1300 097 995.

Share:

More Posts

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X